November 14, 2022 from 7:30 pm – 9:00 pm EST
Philadelphia Marriott Downtown, Grand Ballroom, Salon H, 5th Floor
Rheumatoid arthritis (RA) is a chronic inflammatory arthritis that can cause deformity, loss of function, and decreased quality of life. Since the 1990s, disease-modifying antirheumatic drugs (DMARDs) have been the foundation for RA treatment, initially with synthetic DMARDs and expanding thereafter to include biologic DMARDs and Janus kinase (JAK) inhibitors. JAK inhibitors have established efficacy in RA, but recent safety concerns associated with these drugs, such as an increased potential risk of cancer and cardiovascular events, have healthcare professionals and patients concerned about their use in RA. This program will include a robust discussion of the evidence-based application of recent efficacy and safety data for JAK inhibitors in RA to equip healthcare professionals in helping patients attain low disease activity/remission and improved quality of life.
Welcome and Baseline Polling
Clinical Challenges in RA
News You Can Use: The Latest JAK Inhibitor Efficacy and Safety Data in RA
Putting It Into Context: Risks vs Benefits of JAK Inhibitors in RA
Practical Strategies for Assessing and Managing Individual Patient Risk
Wrap-up and Question and Answer Session
Provided by Clinical Care Options, LLC
This activity is supported by an educational grant from Lilly.
NOT AN OFFICIAL PROGRAM OF THE ACR
Vivian P. Bykerk, MD, FRCPC
Inflammatory Arthritis Center of Excellence
Division of Rheumatology
Hospital for Special Surgery
Professor of Medicine
Weill Cornell Medical College
New York, New York
Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology/Rheumatology
Palo Alto, California
This is not an official program of the American College of Rheumatology.